Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.
Amadori D, Silvestrini R, De Lena M, Boccardo F, Rocca A, Scarpi E, Schittulli F, Brandi M, Maltoni R, Serra P, Ponzone R, Biglia N, Gianni L, Tienghi A, Valerio MR, Bonginelli P, Amaducci L, Faedi M, Baldini E, Paradiso A. Amadori D, et al. Among authors: silvestrini r. Breast Cancer Res Treat. 2011 Feb;125(3):775-84. doi: 10.1007/s10549-010-1257-5. Epub 2010 Dec 4. Breast Cancer Res Treat. 2011. PMID: 21132360 Free article. Clinical Trial.
Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis.
Amadori D, Nanni O, Volpi A, Casadei Giunchi D, Marangolo M, Livi L, Ravaioli A, Rossi AP, Gambi A, Luzi Fedeli S, Perroni D, Scarpi E, Becciolini A, Silvestrini R. Amadori D, et al. Among authors: silvestrini r. Breast Cancer Res Treat. 2008 Mar;108(2):259-64. doi: 10.1007/s10549-007-9593-9. Epub 2007 May 26. Breast Cancer Res Treat. 2008. PMID: 17530429 Clinical Trial.
Benefit from anthracyclines in relation to biological profiles in early breast cancer.
Rocca A, Bravaccini S, Scarpi E, Mangia A, Petroni S, Puccetti M, Medri L, Serra L, Ricci M, Cerasoli S, Biglia N, Maltoni R, Giunchi DC, Gianni L, Tienghi A, Brandi M, Faedi M, Sismondi P, Paradiso A, Silvestrini R, Amadori D. Rocca A, et al. Among authors: silvestrini r. Breast Cancer Res Treat. 2014 Apr;144(2):307-18. doi: 10.1007/s10549-013-2819-0. Epub 2014 Jan 1. Breast Cancer Res Treat. 2014. PMID: 24381054 Clinical Trial.
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial.
Bravaccini S, Bronte G, Scarpi E, Ravaioli S, Maltoni R, Mangia A, Tumedei MM, Puccetti M, Serra P, Gianni L, Amaducci L, Biglia N, Bounous V, Paradiso AV, Silvestrini R, Amadori D, Rocca A. Bravaccini S, et al. Among authors: silvestrini r. Ther Adv Med Oncol. 2020 Feb 27;12:1758835919888999. doi: 10.1177/1758835919888999. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32158505 Free PMC article.
Innovative Breast Cancer Biomarkers.
Paradiso A, Silvestrini R, Chiappetta G. Paradiso A, et al. Among authors: silvestrini r. Breast Care (Basel). 2010;5(2):60-61. doi: 10.1159/000309176. Epub 2010 Apr 13. Breast Care (Basel). 2010. PMID: 20847815 Free PMC article. No abstract available.
c-kit and SCF expression in normal and tumor breast tissue.
Ulivi P, Zoli W, Medri L, Amadori D, Saragoni L, Barbanti F, Calistri D, Silvestrini R. Ulivi P, et al. Among authors: silvestrini r. Breast Cancer Res Treat. 2004 Jan;83(1):33-42. doi: 10.1023/B:BREA.0000010694.35023.9e. Breast Cancer Res Treat. 2004. PMID: 14997053
269 results